Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON study of iberdomide + cyclophosphamide + dexamethasone in relapsed/refractory multiple myeloma
2023-508902-66-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iberdomide, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by Amsterdam University Medical Center. Primary endpoint: Progression-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
iberdomidecyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-508902-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508902-66-00.